Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9

Publication | Closed Access

DOI

Citations

References

2015

Year

Jame Abraham, André Robidoux, Antoinette R. Tan, Steven Limentani, Keren Sturtz, I. Shalaby, Hope G. Alcorn, Marc Buyse, Norman Wolmark, Samuel A. Jacobs

Breast Cancer Research and Treatment

Breast OncologyOncologyNeoadjuvant Chemotherapy RegimensPharmacologyWeekly PaclitaxelBreast CancerPharmacotherapyCancer TreatmentMedicinePhase Ii